<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC6676504\results\search\tropicalVirus\results.xml">
  <result pre="human genetic variability. A phenomenon that controls the kinetics of" exact="DENV" post="infection, antibody-dependent enhancement, best explains the correlation of the"/>
  <result pre="the correlation of the vascular permeability syndrome with second heterotypic" exact="DENV" post="infections and infection in the presence of passively acquired"/>
  <result pre="on growing evidence in vivo and in vitro, the tissue-damaging" exact="DENV" post="non-structural protein 1 (NS1) is responsible for most of"/>
  <result pre="why is the risk of severe disease during second heterotypic" exact="DENV" post="infection so low, why is the onset of vascular"/>
  <result pre="Hill, North Carolina, USA No competing interests were disclosed. Introduction" exact="Dengue" post="viruses (DENVs) are relatively new pathogens. Transmission of virus"/>
  <result pre="development. The four DENVs are genetically related and biologically similar." exact="Dengue" post="is not the only human viral pathogen to circulate"/>
  <result pre="groups, most such outcomes are not well studied or understood." exact="Dengue" post="differs for researchers, a clear-eyed view of the observed"/>
  <result pre="5% of dengue hospitalizations of children 14– 17. Clinical responses" exact="Dengue" post="clinical responses are subject to constraints imposed by infecting"/>
  <result pre="immune status, and human genetic makeup. These are reviewed briefly." exact="Dengue" post="disease severity differs by infection parity. Disease may accompany"/>
  <result pre="children are at higher risk of fatal outcome with heterotypic" exact="DENV" post="infections 33. Exposure to DENV at intervals of less"/>
  <result pre="of fatal outcome with heterotypic DENV infections 33. Exposure to" exact="DENV" post="at intervals of less than 2 years may inhibit"/>
  <result pre="severity 19, 34. Short-term protection and ultimately enhanced second heterotypic" exact="DENV" post="infection outcome may be controlled by natural declines or"/>
  <result pre="or changes in heterotypic antibodies (or both) following a first" exact="DENV" post="infection 35, 36. An increase in disease severity was"/>
  <result pre="first and second infections and the identity of first infecting" exact="DENV" post="type. A subset of severe dengue cases, hemophagocytic lymphohistiocytosis"/>
  <result pre="in Peru successfully tracked household members throughout the city during" exact="DENV" post="transmission seasons 58. For individuals, the risk of DENV"/>
  <result pre="during DENV transmission seasons 58. For individuals, the risk of" exact="DENV" post="infection is controlled by the presence or absence of"/>
  <result pre="(for example, markets or homes of friends or relatives) 59." exact="DENV" post="is not spread significantly by sick individuals. Those who"/>
  <result pre="silent infections may contribute as much as 84% of total" exact="DENV" post="transmission. In persons who do develop dengue disease, most"/>
  <result pre="not simply because of its unexpected linkage to Guillain–Barré syndrome;" exact="Zika" post="infection of pregnant women also caused a congenital Zika"/>
  <result pre="syndrome; Zika infection of pregnant women also caused a congenital" exact="Zika" post="syndrome in infants. There were additional fears that Zika"/>
  <result pre="congenital Zika syndrome in infants. There were additional fears that" exact="Zika" post="infections might enhance DENV infections or vice versa. An"/>
  <result pre="infants. There were additional fears that Zika infections might enhance" exact="DENV" post="infections or vice versa. An entirely unsuspected outcome has"/>
  <result pre="or vice versa. An entirely unsuspected outcome has been that" exact="Zika" post="behaves like a highly effective dengue vaccine. The Zika"/>
  <result pre="that Zika behaves like a highly effective dengue vaccine. The" exact="Zika" post="epidemic of 2015 to 2016 was followed by a"/>
  <result pre="studies in Salvador, Brazil 66, 67. It is suspected that" exact="Zika" post="infection may have served to protect an epidemiologically and"/>
  <result pre="epidemiologically and clinically important group, monotypic dengue-immunes, responsible for secondary" exact="DENV" post="clinical disease 68. A mystery in the global dengue"/>
  <result pre="made to answer this question. A search for a sylvatic" exact="DENV" post="cycle was initiated in a forested area of the"/>
  <result pre="for virus and for antibody conversions with no evidence of" exact="DENV" post="72. Pathogenesis Soon after the DVPS was identified, clinical"/>
  <result pre="clinical and epidemiological data strongly associated it with second heterotypic" exact="DENV" post="infections and also with primary DENV infections of infants"/>
  <result pre="it with second heterotypic DENV infections and also with primary" exact="DENV" post="infections of infants born to dengue-immune mothers 11, 73."/>
  <result pre="dengue-immune mothers 11, 73. Pathology studies have consistently demonstrated human" exact="DENV" post="infection target cells to be of myeloid lineage 74."/>
  <result pre="infection target cells to be of myeloid lineage 74. When" exact="DENV" post="infections occur in vitro or in vivo in the"/>
  <result pre="severity 26, 76, 77. This phenomenon, antibody-dependent enhancement (ADE) of" exact="DENV" post="infection of Fc receptor–bearing cells, differs from infection of"/>
  <result pre="(extrinsic ADE) or an increase in the intracellular production of" exact="DENV" post="(intrinsic ADE) 78. DENV ADE has been observed in"/>
  <result pre="increase in the intracellular production of DENV (intrinsic ADE) 78." exact="DENV" post="ADE has been observed in animal models. Second heterotypic"/>
  <result pre="Efforts to reliably achieve vascular permeability disease during second heterotypic" exact="DENV" post="infections in animals, including mice, have not been successful"/>
  <result pre="in animals, including mice, have not been successful 80. When" exact="DENV" post="antibodies were passively transferred to rhesus monkeys prior to"/>
  <result pre="polyclonal dengue antibodies to mice has regularly resulted in enhanced" exact="DENV" post="infections accompanied by vascular permeability and other features of"/>
  <result pre="to a weakened ability of secondary T cells to contain" exact="DENV" post="infection because of the original antigenic sin phenomenon, (2)"/>
  <result pre="endothelium-damaging secondary infection T-cell cytokines and chemokines, (3) to the" exact="DENV" post="non-structural protein 1 (NS1) heterophile antibodies raised during first"/>
  <result pre="DENV non-structural protein 1 (NS1) heterophile antibodies raised during first" exact="DENV" post="infections that damage platelets, endothelial cells, or blood clotting"/>
  <result pre="passively acquired dengue antibodies. It was long known that fatal" exact="DENV" post="infections of mice could be prevented by anti-NS1 87."/>
  <result pre="prevented by anti-NS1 87. NS1 is produced during all four" exact="DENV" post="infections as well as those of other pathogenic flaviviruses"/>
  <result pre="severe dengue might activate complement to mediate vascular permeability 90." exact="Dengue" post="NS1 has been shown to activate complement by the"/>
  <result pre="complement by the alternative pathway, target liver cells promoting intracellular" exact="DENV" post="infection, complex with thrombin in acute-phase blood of severe"/>
  <result pre="the cellular biology of bacterial lipopolysaccharides (LPSs) and that of" exact="DENV" post="NS1 was discovered 94. Each interacts with TLR4 on"/>
  <result pre="death from lethal DENV2 challenge. Mice immunized with all four" exact="DENV" post="NS1 proteins were completely protected against homologous DENV challenges,"/>
  <result pre="all four DENV NS1 proteins were completely protected against homologous" exact="DENV" post="challenges, whereas immunization with DENV1 NS1 partially protected against"/>
  <result pre="with DENV1 NS1 partially protected against heterologous DENV2 challenge. Furthermore," exact="DENV" post="NS1 was shown to directly alter the barrier function"/>
  <result pre="had been shown to correlate with plasma leakage during severe" exact="DENV" post="infection in humans 97, 98. More recently, the contribution"/>
  <result pre="in humans 97, 98. More recently, the contribution of these" exact="DENV" post="NS1-induced endothelial cell–intrinsic pathways to NS1-mediated vascular leakage was"/>
  <result pre="endothelial glycocalyx components both in vitro and in vivo99. A" exact="DENV" post="NS1 vaccine is taking shape 100. In conclusion, NS1"/>
  <result pre="mechanism of vascular permeability in mice and is controlled by" exact="DENV" post="production in cells and, in turn, by ADE 88."/>
  <result pre="described, DVPS is a rare outcome of a second heterotypic" exact="DENV" post="infection. Identifying those at risk and understanding why they"/>
  <result pre="were collected from children prior to their experiencing second heterotypic" exact="DENV" post="infections, whether overt or silent. Cultured pre-infection PBMCs were"/>
  <result pre="six had elevated responses in children who experienced silent second" exact="DENV" post="infections and three had elevated responses in children who"/>
  <result pre="elevated responses in children who developed symptoms during a subsequent" exact="DENV" post="infection. Significant differences were found in cytokine production based"/>
  <result pre="found in cytokine production based on both the type of" exact="DENV" post="used for stimulation and the occurrence of clinical illness."/>
  <result pre="significantly higher by PBMCs of subjects who later developed symptomatic" exact="DENV" post="infection. These studies are beginning to show how genetic"/>
  <result pre="the Global Advisory Committee on Vaccine Safety, and the WHO" exact="Dengue" post="Vaccine Working Group in 2016 recommended that vaccine be"/>
  <result pre="with known past dengue infection or to populations with 80%" exact="DENV" post="seroprevalence 106. Why did Dengvaxia fail to protect seronegative"/>
  <result pre="children? When vaccinated children developed dengue disease despite circulating tetravalent" exact="DENV" post="neutralizing antibodies, this provided solid evidence that conventionally measured"/>
  <result pre="of virus were attributable to the maturation state 111. Might" exact="DENV" post="maturation status affect biological outcomes of DENV–antibody interactions, such"/>
  <result pre="raised by vaccine may be poorly matched to the specific" exact="DENV" post="genotypes in circulation. Two groups found genetic differences in"/>
  <result pre="cross-protective antibodies analogous to antibodies that develop after natural second" exact="DENV" post="infections with a heterologous serotype 116. These antibodies, which"/>
  <result pre="multifunctional CD8 + T-cell responses were correlated with protection from" exact="DENV" post="disease 117. Functional CD8 + T-cell responses were directed"/>
  <result pre="epitopes on non-structural proteins contribute importantly to homotypic and heterotypic" exact="DENV" post="protective immunity 118, 119. These observations were extended to"/>
  <result pre="to human CD4 + T cells that are primed by" exact="DENV" post="capsid, NS3 and NS5 antigens 120, 121. CD4 +"/>
  <result pre="vaccine mediated efficient viral clearance and superior protection against wild-type" exact="DENV" post="challenge 124. Dengvaxia does not present non-structural DENV proteins"/>
  <result pre="against wild-type DENV challenge 124. Dengvaxia does not present non-structural" exact="DENV" post="proteins to the immune system. Might this absence contribute"/>
  <result pre="DENV2 backbone. The developers hope for successful protection against all" exact="DENV" post="infection/disease on the basis of the broad neutralizing antibody"/>
  <result pre="product, the live-attenuated tetravalent dengue vaccine (LATV), consists of mutated" exact="DENV" post="1, 3 and 4 and a chimera of structural"/>
  <result pre="DENV 1, 3 and 4 and a chimera of structural" exact="DENV" post="2 on a DENV 4 backbone 135– 137. Following"/>
  <result pre="4 and a chimera of structural DENV 2 on a" exact="DENV" post="4 backbone 135– 137. Following a single dose of"/>
  <result pre="123. Finally, LATV contains genes for three of the four" exact="DENV" post="NS1 proteins. LATV is in the third year of"/>
  <result pre="data has been delayed because of an 80% reduction of" exact="DENV" post="cases following the Zika virus epidemic of 2016–17 in"/>
  <result pre="because of an 80% reduction of DENV cases following the" exact="Zika" post="virus epidemic of 2016–17 in Brazil 143. The outlook"/>
  <result pre="World War II.Am J Trop Med Hyg.1952;1(1):30–50. 10.4269/ajtmh.1952.1.3014903434 11NimmannityaSHalsteadSBCohenSNet al.:" exact="Dengue" post="and chikungunya virus infection in man in Thailand, 1962-1964."/>
  <result pre="VI. Hypotheses and discussion.Yale J Biol Med.1970;42:350–62. 5419208 14HalsteadSBLanNTMyintTTet al.:" exact="Dengue" post="hemorrhagic fever in infants: research opportunities ignored.Emerg Infect Dis.2002;8(12):1474–9."/>
  <result pre="in infants: research opportunities ignored.Emerg Infect Dis.2002;8(12):1474–9. 10.3201/eid0812.02017012498666 15ChauTNQuyenNTThuyTTet al.:" exact="Dengue" post="in Vietnamese infants--results of infection-enhancement assays correlate with age-related"/>
  <result pre="F1000 Recommendation 16ChauTNAndersKLLe LienBet al.: Clinical and virological features of" exact="Dengue" post="in Vietnamese infants.PLoS Negl Trop Dis.2010;4(4):e657. 10.1371/journal.pntd.000065720405057 17ClaphamHCummingsDANisalakAet al.:"/>
  <result pre="infants.PLoS Negl Trop Dis.2010;4(4):e657. 10.1371/journal.pntd.000065720405057 17ClaphamHCummingsDANisalakAet al.: Epidemiology of Infant" exact="Dengue" post="Cases Illuminates Serotype-Specificity in the Interaction between Immunity and"/>
  <result pre="Thailand, 1994-2010.BMC Public Health.2015;15:250. 10.1186/s12889-015-1590-z25886528 20NisalakALesslerJTKlungthongCet al.: Forty Years of" exact="Dengue" post="Surveillance at a Tertiary Pediatric Hospital in Bangkok, Thailand,"/>
  <result pre="Recommendation 25ThaiKTPhuongHLThanh NgaTTet al.: Clinical, epidemiological and virological features of" exact="Dengue" post="virus infections in Vietnamese patients presenting to primary care"/>
  <result pre="care facilities with acute undifferentiated fever.J Infect.2010;60(3):229–37. 10.1016/j.jinf.2010.01.00320080126 26VaughnDWGreenSKalayanaroojSet al.:" exact="Dengue" post="viremia titer, antibody response pattern, and virus serotype correlate"/>
  <result pre="Playa municipality, Havana, Cuba, 2001–2002.Int J Infect Dis.2012;16(3):e198–e203. 10.1016/j.ijid.2011.09.02622277259 32HubertBHalsteadSB:" exact="Dengue" post="1 virus and dengue hemorrhagic fever, French Polynesia, 2001.Emerg"/>
  <result pre="Rico, 2008 - 2013.PLoS Negl Trop Dis.2016;10(8):e0004939. 10.1371/journal.pntd.000493927556807 48GiangHTNBannoKMinhLHNet al.:" exact="Dengue" post="hemophagocytic syndrome: A systematic review and meta-analysis on epidemiology,"/>
  <result pre="and risk factors.Rev Med Virol.2018;28(6):e2005. 10.1002/rmv.200530109914 49Wan JamaludinWFPeriyasamyPWan MatWRet al.:" exact="Dengue" post="infection associated hemophagocytic syndrome: Therapeutic interventions and outcome.J Clin"/>
  <result pre="work?PLoS Negl Trop Dis.2013;7(12):e2592. 10.1371/journal.pntd.000259224349598 51LumLCAbdel-LatifMel-AGohAYet al.: Preventive transfusion in" exact="Dengue" post="shock syndrome-is it necessary?J Pediatr.2003;143(5):682–4. 10.1067/S0022-3476(03)00503-114615749 52WhitehornJRodriguez RocheRGuzmanMGet al.:"/>
  <result pre="61QuyenDLThanh LeNVan AnhCTet al.: Epidemiological, Serological, and Virological Features of" exact="Dengue" post="in Nha Trang City, Vietnam.Am J Trop Med Hyg.2018;98(2):402–9."/>
  <result pre="J Trop Med Hyg.2018;98(2):402–9. 10.4269/ajtmh.17-063029313471 62IndrianiCAhmadRAWiratamaBSet al.: Baseline Characterization of" exact="Dengue" post="Epidemiology in Yogyakarta City, Indonesia, before a Randomized Controlled"/>
  <result pre="arms.PLoS One.2019;14(1):e0210041. 10.1371/journal.pone.021004130682037 F1000 Recommendation 66RibeiroGSKikutiMTauroLBet al.: Does immunity after" exact="Zika" post="virus infection cross-protect against dengue?Lancet Glob Health.2018;6(2):e140–e141. 10.1016/S2214-109X(17)30496-529389533 67PerezFLlauAGutierrezGet"/>
  <result pre="of multiple hypotheses.Trop Med Int Health.2019;24(4):442–53. 10.1111/tmi.1320030624838 68RibeiroGSKikutiMTauroLBet al.: Can" exact="Zika" post="virus antibodies cross-protect against dengue virus? - Authors' reply.Lancet"/>
  <result pre="10.1016/j.jcv.2014.08.03025453327 72TurellMJGozaloASGuevaraCet al.: Lack of Evidence of Sylvatic Transmission of" exact="Dengue" post="Viruses in the Amazon Rainforest Near Iquitos, Peru.Vector Borne"/>
  <result pre="virus infections.J Infect Dis.2002;185(9):1213–21. 10.1086/34036512001037 77LamPKTamDTDietTVet al.: Clinical characteristics of" exact="Dengue" post="shock syndrome in Vietnamese children: a 10-year prospective study"/>
  <result pre="CD8 +T Lymphocytes in an Immunocompetent Mouse Model of Secondary" exact="Dengue" post="Virus Infection.EBioMedicine.2017;20:202–16. 10.1016/j.ebiom.2017.04.03328483582 81ZellwegerRMShrestaS: Mouse models to study dengue"/>
  <result pre="late endosomes: implications for viral infectivity.J Virol.2005;79(17):11403–11. 10.1128/JVI.79.17.11403-11411.200516103191 92LinSWChuangYCLinYSet al.:" exact="Dengue" post="virus nonstructural protein NS1 binds to prothrombin/thrombin and inhibits"/>
  <result pre="and inhibits prothrombin activation.J Infect.2012;64(3):325–34. 10.1016/j.jinf.2011.11.02322138554 F1000 Recommendation 93ChaoCHWuWCLaiYCet al.:" exact="Dengue" post="virus nonstructural protein 1 activates platelets via Toll-like receptor"/>
  <result pre="4, leading to thrombocytopenia and hemorrhage.PLoS Pathog.2019;15(4):e1007625. 10.1371/journal.ppat.100762531009511 94ModhiranNWattersonDMullerDAet al.:" exact="Dengue" post="virus NS1 protein activates cells via Toll-like receptor 4"/>
  <result pre="cell monolayer integrity.Sci Transl Med.2015;7(304):304ra142. 10.1126/scitranslmed.aaa386326355031 F1000 Recommendation 95BeattyPRPuerta-GuardoHKillingbeckSSet al.:" exact="Dengue" post="virus NS1 triggers endothelial permeability and vascular leak that"/>
  <result pre="prevented by NS1 vaccination.Sci Transl Med.2015;7(304):304ra141. 10.1126/scitranslmed.aaa378726355030 F1000 Recommendation 96Puerta-GuardoHGlasnerDRHarrisE:" exact="Dengue" post="Virus NS1 Disrupts the Endothelial Glycocalyx, Leading to Hyperpermeability.PLoS"/>
  <result pre="Tight and Adherens Junctions With Severity of Plasma Leakage in" exact="Dengue" post="Infection.J Infect Dis.2017;215(6):992–9. 10.1093/infdis/jix04128453844 98TangTHAlonsoSNgLFet al.: Increased Serum Hyaluronic"/>
  <result pre="98TangTHAlonsoSNgLFet al.: Increased Serum Hyaluronic Acid and Heparan Sulfate in" exact="Dengue" post="Fever: Association with Plasma Leakage and Disease Severity.Sci Rep.2017;7:"/>
  <result pre="Plasma Leakage and Disease Severity.Sci Rep.2017;7: 46191. 10.1038/srep4619128393899 99GlasnerDRRatnasiriKPuerta-GuardoHet al.:" exact="Dengue" post="virus NS1 cytokine-independent vascular leak is dependent on endothelial"/>
  <result pre="on endothelial glycocalyx components.PLoS Pathog.2017;13(11):e1006673. 10.1371/journal.ppat.100667329121099 100EspinosaDABeattyPRReinerGLet al.: Cyclic Dinucleotide-Adjuvanted" exact="Dengue" post="Virus Nonstructural Protein 1 Induces Protective Antibody and T"/>
  <result pre="F1000 Recommendation 102HadinegoroSRArredondo-GarcíaJLCapedingMRet al.: Efficacy and Long-Term Safety of a" exact="Dengue" post="Vaccine in Regions of Endemic Disease.N Engl J Med.2015;373(13):1195–206."/>
  <result pre="to dengue virus.J Virol Methods.2018;257:48–57. 10.1016/j.jviromet.2018.03.00729567514 105SridharSLuedtkeALangevinEet al.: Effect of" exact="Dengue" post="Serostatus on Dengue Vaccine Safety and Efficacy.N Engl J"/>
  <result pre="Virol Methods.2018;257:48–57. 10.1016/j.jviromet.2018.03.00729567514 105SridharSLuedtkeALangevinEet al.: Effect of Dengue Serostatus on" exact="Dengue" post="Vaccine Safety and Efficacy.N Engl J Med.2018;379(4):327–40. 10.1056/NEJMoa180082029897841 F1000"/>
  <result pre="and Efficacy.N Engl J Med.2018;379(4):327–40. 10.1056/NEJMoa180082029897841 F1000 Recommendation 106collab: WHO:" exact="Dengue" post="vaccine: WHO position paper - September 2018.Wkly Epidemiol Rec.2018;93(36):457–76."/>
  <result pre="10.1056/NEJMoa141103725365753 F1000 Recommendation 110KatzelnickLCHarrisE, collab: Participants in the Summit on" exact="Dengue" post="Immune Correlates of Protection: Immune correlates of protection for"/>
  <result pre="State of the art and research agenda.Vaccine.2017;35(36):4659–69. 10.1016/j.vaccine.2017.07.04528757058 111RautRCorbettKSTennekoonRNet al.:" exact="Dengue" post="type 1 viruses circulating in humans are highly infectious"/>
  <result pre="Human Memory B Cell and Serum Neutralizing Antibody Responses to" exact="Dengue" post="Virus Serotype 4 Infection and Vaccination.J Virol.2017;91(5): pii: e02041-16"/>
  <result pre="pii: e02041-16 10.1128/JVI.02041-1628031369 F1000 Recommendation 115GallichotteENBaricTJNivarthiUet al.: Genetic Variation between" exact="Dengue" post="Virus Type 4 Strains Impacts Human Antibody Binding and"/>
  <result pre="Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent" exact="Dengue" post="Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.J Infect Dis.2017;215(3):351–358."/>
  <result pre="in Naive and Dengue-Exposed Individuals.J Infect Dis.2017;215(3):351–358. 10.1093/infdis/jiw57627932620 117WeiskopfDBangsDJSidneyJet al.:" exact="Dengue" post="virus infection elicits highly polarized CX3CR1 + cytotoxic CD4"/>
  <result pre="118WeiskopfDCerpasCAngeloMAet al.: Human CD8 + T-Cell Responses Against the 4" exact="Dengue" post="Virus Serotypes Are Associated With Distinct Patterns of Protein"/>
  <result pre="NgonoAChenHWTangWWet al.: Protective Role of Cross-Reactive CD8 T Cells Against" exact="Dengue" post="Virus Infection.EBioMedicine.2016;13:284–293. 10.1016/j.ebiom.2016.10.00627746192 F1000 Recommendation 120GrifoniAAngeloMALopezBet al.: Global Assessment"/>
  <result pre="Virus Infection.EBioMedicine.2016;13:284–293. 10.1016/j.ebiom.2016.10.00627746192 F1000 Recommendation 120GrifoniAAngeloMALopezBet al.: Global Assessment of" exact="Dengue" post="Virus-Specific CD4 + T Cell Responses in Dengue-Endemic Areas.Front"/>
  <result pre="121TianYSetteAWeiskopfD: Cytotoxic CD4 T Cells: Differentiation, Function, and Application to" exact="Dengue" post="Virus Infection.Front Immunol.2016;7:531. 10.3389/fimmu.2016.0053128003809 122WeiskopfDAngeloMABangsDJet al.: The human CD8"/>
  <result pre="Human CD4 + T Cell Responses to an Attenuated Tetravalent" exact="Dengue" post="Vaccine Parallel Those Induced by Natural Infection in Magnitude,"/>
  <result pre="Restriction, and Antigen Specificity.J Virol.2017;91(5): pii: e02147-16. 10.1128/JVI.02147-1627974563 124LamJHChuaYLLeePXet al.:" exact="Dengue" post="vaccine-induced CD8 + T cell immunity confers protection in"/>
  <result pre="137KirkpatrickBDDurbinAPPierceKKet al.: Robust and Balanced Immune Responses to All 4" exact="Dengue" post="Virus Serotypes Following Administration of a Single Dose of"/>
  <result pre="Administration of a Single Dose of a Live Attenuated Tetravalent" exact="Dengue" post="Vaccine to Healthy, Flavivirus-Naive Adults.J Infect Dis.2015;212(5):702–10. 10.1093/infdis/jiv08225801652 F1000"/>
  <result pre="of the National Institute of Allergy and Infectious Diseases Tetravalent" exact="Dengue" post="Vaccine Induces a Robust Neutralizing Antibody Response.J Infect Dis.2016;214(6):832–5."/>
  <result pre="F1000 Recommendation 141TsaiWYDurbinATsaiJJet al.: Complexity of Neutralizing Antibodies against Multiple" exact="Dengue" post="Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed"/>
  <result pre="Specificity of Antibodies Induced by National Institutes of Health Monovalent" exact="Dengue" post="Virus Vaccines.J Infect Dis.2019;220(2):219–27. 10.1093/infdis/jiz10930895307 143LopesTRRSilvaCSPastorAFet al.: Dengue in"/>
  <result pre="Health Monovalent Dengue Virus Vaccines.J Infect Dis.2019;220(2):219–27. 10.1093/infdis/jiz10930895307 143LopesTRRSilvaCSPastorAFet al.:" exact="Dengue" post="in Brazil in 2017: what happened?Rev Inst Med Trop"/>
 </snippets>
</snippetsTree>
